BMY vs MCK

Bristol-Myers Squibb's Advanced Deterministic Scorecard shows a Piotroski F-Score of 4/9, indicating stable but not strong financial health, while the absence of an Altman Z-Score prevents a definitive distress risk assessment. The stock trades below its growth-based intrinsic value of $87.32 at $54.65, suggesting potential undervaluation, yet the high debt/equity ratio and inconsistent earnings performance temper optimism. Strong profitability metrics like 31.57% operating margin and 33.78% ROE are offset by weak recent earnings growth and bearish insider activity. Analysts consensus is a hold with a $56.96 target, implying limited upside, while the 4.59% dividend yield offers income appeal despite an elevated 83.5% payout ratio.

McKesson Corporation (MCK) presents a compelling investment case supported by robust earnings acceleration, consistent top-line growth, and strong analyst conviction, despite operating in a low-margin, capital-intensive distribution model. The stock has delivered exceptional long-term returns with a 373% five-year gain, underpinned by disciplined execution and favorable healthcare logistics tailwinds. While valuation appears stretched on P/E and the balance sheet lacks transparency, MCK trades at a significant discount to peers on price-to-sales and exhibits superior earnings momentum, with YoY EPS growth nearing 40%. Notably, insider selling raises caution, but the broader fundamental trajectory and sector positioning support continued outperformance.